Details der Publikation - CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review

CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review

Purpose of Review The purpose of the following review is to summarize the most recent understanding of migraine pathophysiology, as well as of basic and clinical science pharmacologic literature regarding the development of calcitonin gene receptor peptide (CGRP) antagonists as a novel therapeutic modality for the treatment of migraine headaches. A review is provided of erenumab, the first of its class FDA approved CGRP antagonist. Recent Findings Despite its high prevalence, the occurrence and treatment of migraine headaches is poorly understood. Erenumab and CGRP antagonists as a whole significantly reduce the average number of migraine days experienced in migraine sufferers. Summary CGRP antagonists appear to significantly improve treatment outcomes in patients who suffer from episodic and chronic migraines. Erenumab is the first CGRP antagonist to be FDA approved for public use; however, further development of biologics in this class is underway..

Medienart:	E-Artikel

Erscheinungsjahr:	2019
Erschienen:	2019

Enthalten in:	Zur Gesamtaufnahme - volume:23
Enthalten in:	Current pain and headache reports - 23(2019), 5 vom: 14. März

Sprache:	Englisch

Beteiligte Personen:	Urits, Ivan [VerfasserIn] Jones, Mark R. [VerfasserIn] Gress, Kyle [VerfasserIn] Charipova, Karina [VerfasserIn] Fiocchi, Jacob [VerfasserIn] Kaye, Alan D. [VerfasserIn] Viswanath, Omar [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

BKL:	44.90$jNeurologie
Themen:	Calcitonin gene receptor peptide (CGRP) antagonist Chronic migraines Episodic migraines Erenumab

Anmerkungen:	© Springer Science+Business Media, LLC, part of Springer Nature 2019

doi:	10.1007/s11916-019-0768-y

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC2103020375

Internformat


LEADER	01000naa a22002652 4500
001	OLC2103020375
003	DE-627
005	20230402073628.0
007	cr uuu---uuuuu
008	230402s2019 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s11916-019-0768-y \|2 doi
035			\|a (DE-627)OLC2103020375
035			\|a (DE-He213)s11916-019-0768-y-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
084			\|a 44.90$jNeurologie \|2 bkl
100	1		\|a Urits, Ivan \|e verfasserin \|4 aut
245	1	0	\|a CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review
264		1	\|c 2019
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Springer Science+Business Media, LLC, part of Springer Nature 2019
520			\|a Purpose of Review The purpose of the following review is to summarize the most recent understanding of migraine pathophysiology, as well as of basic and clinical science pharmacologic literature regarding the development of calcitonin gene receptor peptide (CGRP) antagonists as a novel therapeutic modality for the treatment of migraine headaches. A review is provided of erenumab, the first of its class FDA approved CGRP antagonist. Recent Findings Despite its high prevalence, the occurrence and treatment of migraine headaches is poorly understood. Erenumab and CGRP antagonists as a whole significantly reduce the average number of migraine days experienced in migraine sufferers. Summary CGRP antagonists appear to significantly improve treatment outcomes in patients who suffer from episodic and chronic migraines. Erenumab is the first CGRP antagonist to be FDA approved for public use; however, further development of biologics in this class is underway.
650		4	\|a Chronic migraines
650		4	\|a Episodic migraines
650		4	\|a Calcitonin gene receptor peptide (CGRP) antagonist
650		4	\|a Erenumab
700	1		\|a Jones, Mark R. \|4 aut
700	1		\|a Gress, Kyle \|4 aut
700	1		\|a Charipova, Karina \|4 aut
700	1		\|a Fiocchi, Jacob \|4 aut
700	1		\|a Kaye, Alan D. \|4 aut
700	1		\|a Viswanath, Omar \|4 aut
773	0	8	\|i Enthalten in \|t Current pain and headache reports \|d Springer US, 1997 \|g 23(2019), 5 vom: 14. März \|h Online-Ressource \|w (DE-627)357168402 \|w (DE-600)2094180-8 \|w (DE-576)265627125 \|x 1534-3081 \|7 nnns
773	1	8	\|g volume:23 \|g year:2019 \|g number:5 \|g day:14 \|g month:03
856	4	0	\|u https://dx.doi.org/10.1007/s11916-019-0768-y \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2070
912			\|a GBV_ILN_2086
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2116
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2136
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	b	k	\|a 44.90$jNeurologie \|q VZ \|0 106409980 \|0 (DE-625)106409980
951			\|a AR
952			\|d 23 \|j 2019 \|e 5 \|b 14 \|c 03

CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände